You are here

Taltz

Eli Lilly revs up immunology engine as Olumiant cruises toward coveted alopecia green light

Fierce Pharma

Thu, 05/19/22 - 12:05 pm

As Lilly gears up for key 2022 launches, Trulicity, Taltz and more drive solid growth

Fierce Pharma

Tue, 10/26/21 - 11:54 pm

Novartis takes aim at Eli Lilly with Cosentyx FDA nod in spondyloarthritis

Fierce Pharma

Wed, 06/17/20 - 09:57 am

spondyloarthritis

Eli Lilly's Taltz beats Novartis to the punch with FDA approval in spondyloarthritis

Fierce Pharma

Mon, 06/1/20 - 11:32 pm

axial spondyloarthritis

Eli Lilly's Taltz extends its head-to-head Humira beat with 52-week psoriatic arthritis data

Fierce Pharma

Tue, 11/12/19 - 09:51 am

psoriatic arthritis

Lilly counts on growing markets to boost lagging Taltz, Trulicity

Fierce Pharma

Thu, 10/24/19 - 10:55 am

type 2 diabetes

Lilly's Taltz wins third approval, this time in patients with active ankylosing spondylitis

Endpoints

Mon, 08/26/19 - 09:33 am

monoclonal antibodies

ankylosing spondylitis

Eli Lilly's Taltz bests J&J rival Tremfya in head-to-head psoriasis tilt

Fierce Pharma

Tue, 08/13/19 - 11:40 am

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Pharmaforum

Fri, 06/14/19 - 06:22 pm

psoriatic arthritis

Eli Lilly's Taltz touts long-term clear skin data after unimpressive first-quarter sales

Fierce Pharma

Tue, 06/11/19 - 06:00 pm

Eli Lilly Falls Despite Positive Phase 3 Results From Taltz Study

TheStreet.com

Mon, 04/22/19 - 10:17 am

axial spondyloarthritis

clinical trials

Johnson & Johnson keeps the heat on Tremfya's rivals with at-home injector nod

Fierce Pharma

Fri, 03/1/19 - 11:56 am

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Reuters

Mon, 12/17/18 - 08:15 pm

psoriatic arthritis

clinical trials

Eli Lilly Updates Spondyloarthritis Trial Data and Long-Term Rheumatoid Arthritis Studies

BioSpace

Wed, 10/24/18 - 11:40 pm

Touting PhIII success for arthritis drug Taltz, Eli Lilly chases rival Novartis in heated immunology race

Endpoints

Thu, 06/28/18 - 09:45 am

ankylosing spondylitis

Eli Lilly Builds Case to Expand Immune Drug’s Use to Spinal Arthritis

Xconomy

Tue, 02/13/18 - 11:02 pm

Eli Lilly touts PhIII success for Taltz as rival Novartis stays well out front in crowded immunology race

Endpoints

Tue, 02/13/18 - 09:45 am

ankylosing spondylitis

Lilly's 2018 forecast beats on strength of new drugs

Yahoo/Reuters

Wed, 12/13/17 - 09:41 am

Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nod

Fierce Pharma

Tue, 12/5/17 - 09:30 am

psoriatic arthritis

Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates

Fierce Pharma

Thu, 08/10/17 - 10:47 am

Pages